blenrep gsk fda - Search News

Order byBest matchMost fresh

News

GSK shares fall

· 14h · on MSN

GSK shares fall after blood cancer drug likely headed for U.S. rejection

(Reuters) -GSK shares fell more than 6% on Friday after a U.S. FDA advisory panel recommended against approving its blood cancer drug Blenrep, citing earlier concerns over eye-related side effects. The British drugmaker was trying to revive the drug,

Continue reading

GSK blood cancer drug fails to win backing of key US regulatory panel

· 23h · on MSN

FDA Committee Votes Against GSK Blood Cancer Drug Blenrep

GSK’s Blenrep Loses Adcomm Vote, Further Clouding Comeback Bid

The panelists flagged safety concerns with Blenrep and GSK’s failure to optimize its dosing regimen for the antibody-drug ...

‘Surprising’ setback: ODAC rebuffs Blenrep for multiple myeloma, citing ocular toxicity

An FDA advisory committee ruled in two separate votes that two belantamab mafodotin combination regimens should not be used ...

Pharmalittle: We’re reading about a GSK setback, another Sarepta gene therapy death, and more

In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results